氣喘與慢性阻塞性肺病的趨勢及變化

肺阻塞佔世界死因排名第四,預估將持續攀升。越來越多國際藥廠投入相關治療用藥,市場也發生了明顯的變化。LABA聯合LAMA將取代ICS聯合LABA FDC,成為肺阻塞的主要治療選擇並持續增長。而ICS聯合LABA FDC在氣喘治療的競爭更加激烈,差異化需求逐漸增加。 Chronic obstructive pulmonary disease (COPD) is now the fourth leading cause of death worldwide and is predicted by WHO to become the third by 2030. More and more international pharmaceuticals have increased investment in treatments for respiratory diseases, bringing significant changes to COPD and Asthma treatment market. LABA/LAMA has replaced ICS/LABA FDC to become the leading treatment choice for COPD and will continue its growth. We also found Increased competition of ICS/LABA FDC as asthma treatment, as well as the needs for differentiation.

氣喘與慢性阻塞性肺病的趨勢及變化

慢性阻塞型肺病(Chronic obstructive pulmonary disease,COPD),又稱肺阻塞,是一種漸進性的慢性肺功能退化疾病,隨著病情的進展,會有呼吸困難、咳痰、喘不過氣等症狀發生。根據世界衛生組織統計,全世界每年至少有300萬人死於肺阻塞,佔全世界死因排名第四位,預測至2020年將攀升至第三位。根據衛生福利部國民健康署提供的資料顯示,在台灣每年至少有5000人因肺阻塞死亡,在106年更高達近7000人死於肺阻塞。
同為常見呼吸道疾病的氣喘(Asthma) 是一種可逆的慢性呼吸道炎性疾病,常見症狀為胸悶,咳嗽或呼吸困難。根據世界衛生組織的資料顯示,全球約有3億人罹患氣喘,每年因為氣喘導致死亡的人數近18萬人。雖然氣喘現已有方便有效的治療方式,但據衛生福利部國民健康署提供的資料顯示,每年台灣仍有約1500人死於氣喘,且隨著患者年齡的增加,死亡率也逐漸上升。
Chronic obstructive pulmonary disease (COPD) is a progressive chronic degenerative lung disease characterized by worsening of symptoms, including difficulty breathing, excessive mucus, and shortness of breath, through the course of disease. WHO estimates there are at least 3 million people died of COPD a year. COPD is now the fourth leading cause of death worldwide and is predicted by WHO to become the third by 2030. According to the estimates from Health Promotion Administration, Ministry of Health and Welfare (HPA), COPD takes away at least 5000 lives in Taiwan every year. The number reaches nearly 7000 in 2017. 
Asthma, another common respiratory disease, is a reversible, chronic disease that inflames the airways in the lungs. Common symptoms are chest tightness, coughing and shortness of breath. According to the WHO’s evaluation, about 300 million people suffer from Asthma, and the number of asthma-caused death reaches around 0.18 million every year. Despite effective treatments for asthma are available, HPA estimates there are about 1500 people died of asthma every year with mortality rising with age. 
Recently, more and more international pharmaceuticals have increased investment in treatments for respiratory diseases, bringing significant changes to COPD and Asthma treatment market.
 

Society